EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Delayed ART in a HER2+ Breast Cancer Patient with HIV: Clinical Deterioration and Recovery

Aya Said Allan

Middle Eastern Cancer and Oncology Journal · 02.03.2026 · 2 (1) · 48-54

DOI: 10.61706/mecoj160182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Middle Eastern Cancer and Oncology Journal, online erschienen am 02.03.2026. Verfasst von Aya Said Allan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with HIV who are receiving chemotherapy for breast cancer face a state of immunosuppression that is further exacerbated by the chemotherapy. It has been demonstrated that cases of HER2-positive breast cancer, which require intensive treatment, are particularly vulnerable if antiretroviral therapy (ART) is delayed. A 42-year-old woman with a recent diagnosis of stage IIIB HER2-positive breast cancer and a newly detected HIV infection had antiretroviral therapy (ART) deferred, despite having a CD4 count of 350 cells/mm³. During the course of chemotherapy, the patient's CD4 count decreased to 190 cells/mm³, while her viral load increased to 66,000 copies/mL. The patient exhibited symptoms including neutropenia, oral candidiasis, and bacterial infections. The administration of ART occurred midway through the treatment regimen. Subsequent microbiological diagnostics (VITEK 2 system) revealed the presence of ESBL-producing Klebsiella pneumoniae. The therapeutic approach was adapted in accordance with the patients' susceptibility to the treatment and their respective renal function. The patient's clinical status was stabilized, as evidenced by an increase in CD4 count to 265 cells/mm³ and a decrease in viral load to 7,000 copies/mL. The initiation of antiretroviral therapy (ART) at an early stage, the incorporation of microbiological guidance, and the coordination of care among multiple disciplines are pivotal in enhancing outcomes for HIV-positive patients undergoing cancer therapy.

Zitieren

APA

Allan, A. S. (2026). Delayed ART in a HER2+ Breast Cancer Patient with HIV: Clinical Deterioration and Recovery. Middle Eastern Cancer and Oncology Journal, 2(1), 48-54. https://doi.org/10.61706/mecoj160182

Vancouver

Allan AS. Delayed ART in a HER2+ Breast Cancer Patient with HIV: Clinical Deterioration and Recovery. Middle Eastern Cancer and Oncology Journal. 2026;2(1):48-54. doi:10.61706/mecoj160182

BibTeX
@article{Allan2026,
  author = {Allan, Aya Said},
  title = {Delayed ART in a HER2+ Breast Cancer Patient with HIV: Clinical Deterioration and Recovery},
  journal = {Middle Eastern Cancer and Oncology Journal},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {48--54},
  doi = {10.61706/mecoj160182}
}
Kostenlos starten →